Moderna and Merck Present Phase 3 Melanoma Data on Personalized Cancer Vaccine
Moderna and Merck present Phase 3 melanoma findings for their personalized mRNA cancer vaccine; endpoints, effect sizes and filing plans await full disclosure.
Topic
Pembrolizumab
Topic
Pembrolizumab
Keytruda Plus mRNA Vaccine Shows Promise in Skin Cancer Trial
Merck's Keytruda paired with a personalized mRNA vaccine produced 'promising' results in a skin cancer trial, the company reporte…
Moderna, Merck Say mRNA Melanoma Vaccine Succeeded in Phase 3
Moderna and Merck say their personalized mRNA cancer vaccine succeeded in a Phase 3 melanoma trial — a first for the mRNA platfor…
Moderna–Merck Melanoma Combo Cuts Spread Risk at Five Years
Moderna and Merck report their mRNA cancer vaccine–pembrolizumab combination cut the risk of melanoma spread at five years, a dur…
mRNA Cancer Vaccine Plus Keytruda Boosts Melanoma Survival
An mRNA cancer vaccine combined with Keytruda sharply improved survival in melanoma patients, UCHealth trial results show, advanc…